KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to $3.0 billion.

  • Eli Lilly's Cost of Revenue rose 3858.02% to $3.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 billion, marking a year-over-year increase of 2924.19%. This contributed to the annual value of $8.4 billion for FY2024, which is 1886.56% up from last year.
  • According to the latest figures from Q3 2025, Eli Lilly's Cost of Revenue is $3.0 billion, which was up 3858.02% from $2.4 billion recorded in Q2 2025.
  • Over the past 5 years, Eli Lilly's Cost of Revenue peaked at $3.0 billion during Q3 2025, and registered a low of $1.4 billion during Q2 2022.
  • For the 5-year period, Eli Lilly's Cost of Revenue averaged around $2.0 billion, with its median value being $1.9 billion (2021).
  • Its Cost of Revenue has fluctuated over the past 5 years, first skyrocketed by 5983.63% in 2021, then crashed by 2676.12% in 2022.
  • Over the past 5 years, Eli Lilly's Cost of Revenue (Quarter) stood at $2.1 billion in 2021, then decreased by 24.49% to $1.5 billion in 2022, then increased by 15.5% to $1.8 billion in 2023, then soared by 34.44% to $2.4 billion in 2024, then increased by 25.15% to $3.0 billion in 2025.
  • Its Cost of Revenue was $3.0 billion in Q3 2025, compared to $2.4 billion in Q2 2025 and $2.2 billion in Q1 2025.